April 11, 2022

Winship Invest$ names pilot grant awardees

Photo of Winship Invest$ names pilot grant awardees

Eleven investigators will receive a total of $700,000 in funding for new cancer research projects through Winship Invest$.

Eleven investigators will receive a total of $700,000 in funding for new cancer research projects through Winship Invest$, a peer-reviewed program designed to fund novel, innovative cancer research at Winship Cancer Institute of Emory University.

Winship Invest$ is supported by philanthropic contributions as well as developmental funds from Winship's Cancer Center Support Grant (P30CA138292) awarded by the National Cancer Institute of the National Institutes of Health.

Winship Invest$ has two funding cycles every year and solicits proposals in strategic research domains. The most recent call for proposals focused on projects related to team science, early-career investigators, and Winship's four research programs.

This cycle's Winship Invest$ pilot grant recipients are below.

  • Adaptive immune responses to COVID-19 and influenza vaccine in patients with lymphoma
    Andres Chang, MD, PhD
  • Molecular Imaging of the Hypoxic Tumor Microenvironment to Predict Response to Yttrium-90 Selective Internal Radiation Therapy in Hepatocellular Carcinoma
    Nima Kokabi, MD
  • Development of a pancreatic cancer no viral delivery system
    Leon Bernal-Mizrachi, MD
  • Investigating the oncogenic roles of AMPK in LKB1-mutant LUAD
    Melissa Gilbert-Ross, PhD
  • Mechanisms of chemotherapy resistance in SMARCB1-deficient childhood cancers
    Andrew Hong, MD
  • A Technology-Based Colorectal Cancer Information Coaching/Support Program for Asian American Women
    Eun-Ok Im, PhD, MPH, RN, CNS, FAAN
  • Biomarker-Based Approaches to Understand and Predict Cardiovascular Toxicity from Androgen Deprivation Therapy Targeting the Gonadotropin Releasing Hormone Pathway
    Brian Olson, PhD
  • Enhanced Abscopal Responses with IAP Antagonism
    Nicole Schmitt, MD
  • General Modulating Mitochondrial Dynamics to Enhance Therapeutic T Cell Expansion and Persistence
    Mala Shanmugam, PhD
  • A Phase I study of subcutaneously administered natural progesterone for the treatment of recurrent GBM
    Hui-Kuo Shu, MD, PhD
  • Targeting FGFR4 signaling to potentiate antitumor immunity
    Yong Teng, PhD
Cascade Link  TOP